Subcutaneous Immunotherapy Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Subcutaneous Immunotherapy. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Subcutaneous Immunotherapy Indian Medical PG Question 1: Which of the following regarding the vaccine vial monitor (VVM) is true?
1. It is used for monitoring heat exposure of the vaccine by healthcare workers in primary healthcare.
2. It shows cumulative exposure of the vaccine to the heat.
3. It can be used to assess the potential efficacy of the vaccine
4. Calculation of the expiry date can be done using VVM.
5. The expiry date of the vaccine can be relaxed if VVM is an acceptable range.
6. If the square and the circle are the same in color, then the vaccine can be safely used.
- A. 1,2,3,4,5
- B. 3,4
- C. 1,2 (Correct Answer)
- D. 5,6
Subcutaneous Immunotherapy Explanation: ***Correct: Statements 1, 2***
**Statement 1 - TRUE**: The VVM is primarily designed for **healthcare workers** to monitor vaccine heat exposure at all levels, including primary healthcare settings. This is a key WHO tool for cold chain monitoring.
**Statement 2 - TRUE**: VVMs provide a **cumulative record** of time and temperature exposure, reflecting the total heat stress a vaccine has experienced throughout its journey from manufacturer to administration.
*Statement 3 - FALSE*
- While VVMs assess heat exposure that affects vaccine stability, they do **not directly measure vaccine efficacy** or provide quantitative measures of immune response potential.
- Heat damage indicated by VVM indirectly suggests reduced potency, but the VVM itself cannot assess efficacy.
*Statement 4 - FALSE*
- VVMs are **not used to calculate expiry dates**. Manufacturing expiry dates are determined through stability studies under controlled conditions by the manufacturer.
*Statement 5 - FALSE*
- The **expiry date cannot be relaxed or extended** based on VVM status. The manufacturer's stated expiry date must always be respected regardless of how favorable the VVM reading is.
*Statement 6 - FALSE*
- This is the **opposite** of how VVM works. If the **inner square is the same color or darker than the outer circle**, the vaccine has been exposed to excessive heat and **should NOT be used**.
- The vaccine is safe when the inner square is lighter than the outer circle.
Subcutaneous Immunotherapy Indian Medical PG Question 2: Therapeutic exposure is a core technique primarily used in which type of therapy?
- A. Behavior therapy with exposure techniques (Correct Answer)
- B. Cognitive therapy modifying thought patterns
- C. Supportive therapy providing emotional support
- D. Psychoanalysis focusing on unconscious conflicts
Subcutaneous Immunotherapy Explanation: ***Behavior therapy with exposure techniques***
- **Exposure therapy** is a core component of **behavior therapy**, specifically designed to address **anxiety disorders** and phobias by gradually exposing individuals to feared stimuli.
- The goal is to reduce fear and avoidance behaviors by helping the individual learn that the feared object or situation is harmless and that their anxiety will naturally decrease over time (habituation).
*Cognitive therapy modifying thought patterns*
- **Cognitive therapy** focuses on identifying and changing **maladaptive thought patterns** and beliefs that contribute to psychological distress.
- While it may be combined with behavioral techniques, **exposure** itself is not its primary methodology but rather a behavioral intervention.
*Supportive therapy providing emotional support*
- **Supportive therapy** aims to reduce distress by offering **emotional support**, encouragement, and practical advice, helping patients cope with current stressors.
- It does not typically involve structured techniques like exposure to modify specific behaviors or thought patterns, but rather a more empathetic and less directive approach.
*Psychoanalysis focusing on unconscious conflicts*
- **Psychoanalysis** is a long-term, intensive therapy that explores **unconscious conflicts**, repressed memories, and past experiences to bring them to conscious awareness.
- Its techniques include **free association**, dream analysis, and transference interpretation, rather than direct exposure to feared stimuli.
Subcutaneous Immunotherapy Indian Medical PG Question 3: What is the most appropriate method for administering asthma treatment to an infant under one year of age?
- A. MDI with Mask (no spacer)
- B. Nebulizer therapy
- C. MDI with Spacer (no mask)
- D. MDI with Spacer and Mask (Correct Answer)
Subcutaneous Immunotherapy Explanation: ***MDI with Spacer and Mask***
- For infants and young children, a **metered-dose inhaler (MDI)** used with a **spacer** and a **well-fitting mask** is the **most appropriate** method for delivering asthma medication.
- The spacer helps to reduce the velocity of the aerosol and allows the infant to inhale the medication over several breaths, while the mask ensures the medication is delivered to the airways without significant loss.
- This method is **portable**, **convenient**, and **cost-effective** for routine outpatient management.
*MDI with Spacer (no mask)*
- While a spacer is crucial for optimizing drug delivery from an MDI, an infant cannot effectively seal their lips around a spacer mouthpiece for proper inhalation.
- This method would result in significant **medication loss** and insufficient dose delivery to the lungs.
*MDI with Mask (no spacer)*
- An MDI used directly with a mask without a spacer leads to inefficient drug delivery due to the **high velocity** of the aerosol spray.
- The medication impinges on the back of the throat and face, reducing the amount that reaches the small airways.
*Nebulizer therapy*
- Nebulizers are also an **acceptable and effective option** for infants, particularly in acute settings or when families find them easier to use.
- However, they are **time-consuming** (typically 10-15 minutes per treatment), require a power source or batteries, and are less portable than MDI systems.
- For **routine outpatient management**, an MDI with spacer and mask is generally **preferred** due to its convenience, portability, and comparable efficacy when used correctly.
Subcutaneous Immunotherapy Indian Medical PG Question 4: Which of the following is false regarding transfusion-associated anaphylactic reactions?
- A. Different from allergy
- B. Epinephrine is the drug of choice
- C. Washed blood products prevent it
- D. Seen in IgG deficient individuals (Correct Answer)
Subcutaneous Immunotherapy Explanation: ***Seen in IgG deficient individuals***
- Transfusion-associated **anaphylactic reactions** are most commonly seen in **IgA-deficient individuals** who develop **anti-IgA antibodies** and receive blood products containing IgA.
- Anaphylaxis occurs when these pre-formed IgA antibodies react with donor IgA, leading to mast cell degranulation and severe allergic symptoms.
*Different from allergy*
- Transfusion-associated **anaphylactic reactions** are a severe form of allergic reaction, often distinguished by their **rapid onset** and life-threatening nature [1].
- While all allergies involve an immune response to an allergen, anaphylaxis represents the most extreme systemic manifestation.
*Epinephrine is the drug of choice*
- **Epinephrine** is indeed the **first-line treatment** for acute anaphylaxis, regardless of its cause, including transfusion-associated reactions [2].
- It acts rapidly to counteract the systemic effects of histamine and other mediators by acting on α and β adrenergic receptors [3].
*Washed blood products prevent it*
- **Washing blood products** (e.g., packed red blood cells or platelets) is an effective strategy to **remove plasma proteins**, including IgA.
- This is particularly crucial for patients with a known **IgA deficiency and anti-IgA antibodies** to prevent severe anaphylactic reactions.
Subcutaneous Immunotherapy Indian Medical PG Question 5: Which of the following are early mediators of allergic rhinitis?
- A. Leukotrienes
- B. Interleukin-4
- C. Interleukin-5
- D. Platelet-activating factor and bradykinin (Correct Answer)
Subcutaneous Immunotherapy Explanation: ### Explanation
Allergic rhinitis is a Type I hypersensitivity reaction occurring in two distinct phases: the **Early Phase** (within minutes) and the **Late Phase** (4–8 hours later).
**Why Option D is Correct:**
The early phase is triggered when an allergen cross-links IgE antibodies on the surface of **mast cells**, leading to immediate degranulation. This releases **pre-formed mediators** and rapidly synthesized lipid mediators.
* **Histamine** is the primary mediator.
* **Platelet-activating factor (PAF), Bradykinin, and Prostaglandin D2** are also released during this immediate window, causing vasodilation, increased vascular permeability (edema), and stimulation of sensory nerves (itching/sneezing).
**Why Other Options are Incorrect:**
* **A. Leukotrienes:** While Cysteinyl Leukotrienes (CysLTs) are produced during the early phase, they are most characteristic of the transition to and maintenance of the **Late Phase** response, contributing significantly to prolonged nasal congestion.
* **B & C. Interleukin-4 and Interleukin-5:** These are **cytokines** produced by Th2 lymphocytes. They are involved in the **Late Phase** response. IL-4 promotes IgE isotype switching, while IL-5 is the primary factor for **eosinophil** recruitment and activation.
**NEET-PG High-Yield Pearls:**
1. **Early Phase (Minutes):** Mediated by Mast cells. Key symptoms: Sneezing, itching, rhinorrhea. Key mediator: Histamine.
2. **Late Phase (Hours):** Mediated by Eosinophils, Basophils, and Th2 cells. Key symptom: Nasal congestion.
3. **Gold Standard Diagnosis:** Skin Prick Test (detects specific IgE).
4. **Pharmacology Link:** Antihistamines work best on early-phase symptoms (itch/sneeze), while Intranasal Steroids are the most effective treatment for late-phase symptoms (congestion) because they inhibit cytokine release.
Subcutaneous Immunotherapy Indian Medical PG Question 6: Which of the following is the preformed toxin involved in the mechanism of allergic rhinitis?
- A. Histamine (Correct Answer)
- B. Leukotriene
- C. TXA2
- D. PGD2
Subcutaneous Immunotherapy Explanation: ### Explanation
The pathophysiology of Allergic Rhinitis is a **Type I Hypersensitivity reaction** mediated by IgE. When an allergen cross-links IgE antibodies on the surface of mast cells, it triggers **degranulation**, leading to the release of two types of inflammatory mediators:
**1. Why Histamine is Correct:**
Histamine is a **preformed mediator** stored in the granules of mast cells and basophils. Upon activation, it is released immediately (within minutes), causing the "Early Phase" response characterized by sneezing, itching, and rhinorrhea. Because it is synthesized and stored *before* the allergic trigger occurs, it is classified as a preformed toxin/mediator.
**2. Why the Other Options are Incorrect:**
* **Leukotrienes (B), TXA2 (C), and PGD2 (D):** These are **newly synthesized mediators** (lipid-derived). They are not stored in granules but are produced *de novo* from arachidonic acid via the cyclooxygenase (COX) or lipoxygenase (LOX) pathways only after the mast cell is activated. These mediators typically contribute to the "Late Phase" response, leading to nasal congestion and sustained inflammation.
### NEET-PG High-Yield Pearls:
* **Early Phase (Minutes):** Primarily mediated by **Histamine**. Clinical features: Sneezing, itching, watery rhinorrhea.
* **Late Phase (4–8 hours):** Mediated by **Leukotrienes (LTC4, LTD4, LTE4)**, Cytokines, and PGD2. Clinical feature: Nasal congestion (due to cellular infiltration, mainly eosinophils).
* **Gold Standard Investigation:** Skin Prick Test (detects specific IgE).
* **Drug of Choice:** Intranasal Corticosteroids (act on both early and late phases).
* **Mast Cell Stabilizer:** Sodium Cromoglycate (prevents degranulation; used prophylactically).
Subcutaneous Immunotherapy Indian Medical PG Question 7: Paracusis willis is a feature of which condition?
- A. Tympanosclerosis
- B. Otosclerosis (Correct Answer)
- C. Meniere's disease
- D. Presbyacusis
Subcutaneous Immunotherapy Explanation: **Explanation:**
**Paracusis Willis** is a clinical phenomenon where a patient with hearing loss paradoxically hears better in a noisy environment than in a quiet one.
**Why Otosclerosis is correct:**
Otosclerosis is a condition characterized by the fixation of the stapes footplate, leading to **conductive hearing loss (CHL)**. In a noisy environment, normal-hearing individuals naturally raise their voice volume (the Lombard effect) to overcome background noise. A patient with Otosclerosis has a "conductive barrier" that filters out the low-frequency background noise, but because their inner ear and nerve function are intact, they can clearly perceive the loud, raised voices of others. This makes their hearing appear improved in noisy settings.
**Why other options are incorrect:**
* **Tympanosclerosis:** While this causes CHL due to hyalinization of the tympanic membrane, Paracusis Willis is classically described and most significantly associated with the stapes fixation found in Otosclerosis.
* **Meniere’s Disease:** This is a sensory-neural hearing loss (SNHL) condition. Patients typically suffer from **loudness recruitment**, making noisy environments distressing rather than helpful.
* **Presbyacusis:** This is age-related SNHL. These patients struggle significantly in noise due to poor speech discrimination and the loss of high-frequency clarity.
**Clinical Pearls for NEET-PG:**
* **Schwartz Sign:** A flamingo-pink flush seen on the promontory through the TM (indicates active otosclerosis/otospongiosis).
* **Carhart’s Notch:** A characteristic dip in the bone conduction threshold at **2000 Hz**.
* **Gelle’s Test:** Negative in Otosclerosis (indicates an immobile ossicular chain).
* **Treatment of Choice:** Stapedotomy (using a Teflon piston).
Subcutaneous Immunotherapy Indian Medical PG Question 8: What is the full form of ARIA?
- A. Allergic rhinitis and its impact on asthma (Correct Answer)
- B. Allergic rhinitis induced asthma
- C. Antibody response in allergic rhinitis
- D. Antibody response in asthma
Subcutaneous Immunotherapy Explanation: **Explanation:**
**1. Why Option A is Correct:**
ARIA stands for **Allergic Rhinitis and its Impact on Asthma**. It is a global initiative launched by the World Health Organization (WHO) in 1999 (published in 2001) to provide evidence-based guidelines for the management of allergic rhinitis. The core medical concept behind ARIA is the **"United Airway Disease"** hypothesis, which posits that the upper and lower airways are a single functional unit. Inflammation in the nasal mucosa (allergic rhinitis) often coexists with and exacerbates inflammation in the bronchial tree (asthma).
**2. Why Other Options are Incorrect:**
* **Option B:** While allergic rhinitis is a major risk factor for developing asthma, ARIA is the name of the *guideline/initiative*, not a description of the pathophysiology of "induced" asthma.
* **Options C & D:** These are distractors. While ARIA guidelines discuss IgE-mediated antibody responses, the acronym itself does not stand for "Antibody Response."
**3. High-Yield Clinical Pearls for NEET-PG:**
* **Classification:** ARIA replaced the old "seasonal/perennial" classification with a more clinical approach based on duration and severity:
* **Intermittent:** Symptoms < 4 days/week OR < 4 consecutive weeks.
* **Persistent:** Symptoms > 4 days/week AND > 4 consecutive weeks.
* **Severity:** Categorized as **Mild** (normal sleep/daily activities) or **Moderate-Severe** (disturbed sleep/impairment of daily activities).
* **Treatment Strategy:** Intranasal corticosteroids (INCS) are the first-line treatment for moderate-to-severe persistent rhinitis.
* **The Link:** Approximately 80% of asthmatics have co-existing allergic rhinitis, and up to 40% of patients with allergic rhinitis have asthma. Treatment of the nose often improves asthma control.
Subcutaneous Immunotherapy Indian Medical PG Question 9: A 29-year-old non-smoker man presents with sneezing, post-nasal drip, eye watering, and itching of his posterior pharynx. These symptoms tend to be worse in the spring and summer and have been bothering him for about 1 month. His past medical history is remarkable only for mild asthma induced by being outdoors. He takes no regular medications but does take diphenhydramine on occasion. What is the most appropriate diagnostic test at this time?
- A. Blood radioallergosorbent test
- B. None, the diagnosis is based solely on the history and physical examination (Correct Answer)
- C. Intradermal testing
- D. Serum protein electrophoresis
Subcutaneous Immunotherapy Explanation: **Explanation:**
The patient presents with classic symptoms of **Allergic Rhinitis (AR)**: paroxysmal sneezing, post-nasal drip, ocular symptoms (watering), and palatal itching. The seasonal pattern (spring/summer) and comorbid asthma strongly support this diagnosis.
**1. Why the Correct Answer is Right:**
In clinical practice, the diagnosis of Allergic Rhinitis is primarily **clinical**, based on a suggestive history and physical examination (e.g., pale/bluish nasal mucosa, allergic shiners). According to the **ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines**, specialized allergy testing is not required to initiate empirical treatment (such as intranasal corticosteroids or oral antihistamines). Testing is generally reserved for patients who fail medical therapy, have atypical symptoms, or are candidates for immunotherapy.
**2. Why the Other Options are Wrong:**
* **Option A (RAST):** The Radioallergosorbent test measures allergen-specific IgE in the blood. While useful if skin testing is contraindicated (e.g., severe eczema), it is less sensitive and more expensive than skin prick testing and is not a first-line diagnostic requirement.
* **Option C (Intradermal Testing):** This is a more sensitive form of skin testing but carries a higher risk of systemic reactions. It is typically used only when Skin Prick Tests are negative despite a strong clinical suspicion.
* **Option D (Serum Protein Electrophoresis):** This is used to diagnose monoclonal gammopathies (like Multiple Myeloma) or immune deficiencies; it has no role in the diagnosis of allergic rhinitis.
**Clinical Pearls for NEET-PG:**
* **First-line treatment for AR:** Intranasal corticosteroids (e.g., Fluticasone).
* **Allergic Salute:** A transverse crease across the lower bridge of the nose caused by repeated upward rubbing.
* **Semenov’s Sign:** Edema of the soft palate, often seen in chronic allergic rhinitis.
* **Definitive Treatment:** Allergen-specific immunotherapy (SIT) is the only treatment that can modify the natural course of the disease.
Subcutaneous Immunotherapy Indian Medical PG Question 10: What are the early mediators of allergic rhinitis?
- A. Leukotrienes
- B. IL-4
- C. IL-5
- D. All of the above (Correct Answer)
Subcutaneous Immunotherapy Explanation: Allergic rhinitis is a Type I hypersensitivity reaction mediated by IgE. When a sensitized individual is exposed to an allergen, it triggers a complex cascade involving both early and late-phase responses.
**Explanation of the Correct Answer:**
The correct answer is **D (All of the above)** because the early phase of the allergic response (occurring within minutes) and the transition to the late phase involve a cocktail of pre-formed and newly synthesized mediators:
* **Leukotrienes (C4, D4, E4):** These are potent lipid mediators synthesized via the lipoxygenase pathway. They cause marked vasodilation, increased vascular permeability, and mucus hypersecretion.
* **IL-4:** This cytokine is crucial for the "isotype switching" of B-cells to produce IgE. It is released early by Th2 cells and mast cells to propagate the allergic cascade.
* **IL-5:** This is the primary cytokine responsible for the recruitment, activation, and survival of **eosinophils**, which are the hallmark cells of the late-phase response.
**Why other options are considered together:**
While Histamine is the classic "pre-formed" mediator of the immediate phase, Leukotrienes and Th2-derived cytokines (IL-4, IL-5) are synthesized and released rapidly enough to be categorized as mediators of the early allergic environment that sets the stage for clinical symptoms.
**High-Yield Clinical Pearls for NEET-PG:**
* **Mast Cells:** The central cell in the early phase; they undergo degranulation upon cross-linking of IgE receptors.
* **Eosinophils:** The central cell in the **late-phase response** (occurring 4–8 hours later).
* **Pharmacology Link:** Montelukast is a Leukotriene Receptor Antagonist (LTRA) used specifically to block the effects of the leukotrienes mentioned in Option A.
* **Cytokine Shortcut:** Remember **"IL-4 makes IgE, IL-5 activates Eosinophils."**
More Subcutaneous Immunotherapy Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
